Vigilant Biosciences Announces Poster Presentation on Multivariate Oral Rinse Models for Prediction of Head and Neck Squamous Cell Carcinoma at the 6th International Conference on Innovative Approaches in Head and Neck Oncology
March 15, 2017
Fort Lauderdale, Fla. and Barcelona, Spain
Vigilant Biosciences, Inc., a leading innovator and developer of solutions that aid in the early detection and intervention of cancer, today announced a poster presentation of data related to studies conducted to better understand the performance characteristics of a combined salivary CD44 and total protein assay in the diagnosis of head and neck squamous cell carcinoma (HNSCC). The studies, along with others, helped provide direction for the clinical application of Vigilant Biosciences OncAlert® Oral Cancer and OncAlert Labs product lines as well as pipeline programs under development.
The study, titled, “Multivariate oral rinse models predict Head and Neck squamous cell carcinoma (HNSCC),” demonstrates the ability to identify the presence of the tumor-initiating and stem cell-associated biomarker CD44 and total protein, in a simple oral rinse, to potentially indicate an elevated risk for oral cancer, even prior to the observation of visual or physical symptoms.
The data will be presented at the 6th International Conference on Innovative Approaches in Head and Neck Oncology (ICHNO), which will be held March 16-18, 2017, in Barcelona, Spain.
Details for the poster session are as follows:
Title: “Multivariate oral rinse models predict Head and Neck squamous cell carcinoma (HNSCC)”
Presenter: Matthew H.J. Kim, J.D., Founder, Chairman and CEO, Vigilant Biosciences, Inc.
The poster will be displayed at the conference venue throughout the length of the conference. Vigilant Biosciences will also be available to discuss its poster during the welcome reception, which will be held on Thursday, March 16, from 7:00 – 10:00 PM (CET).
The full schedule of events can be viewed at http://estro.org/congresses-meetings/items/6th-ichno.
About Vigilant Biosciences Products
Vigilant Biosciences OncAlert Oral Cancer product line is based on patented technology that measures soluble CD44, a tumor-initiating and stem cell-associated biomarker, and total protein levels – markers clinically validated to be associated specifically with oral cancer – to aid clinicians in the early detection and intervention of oral cancer. The simple, oral rinse procedure is easy to administer and non-invasive for the patient. Vigilant’s products currently include the
OncAlert Labs OraMarkTM Test, a laboratory developed test available only through OncAlert Labs, a CLIA certified laboratory; and the OncAlert Oral Cancer product line, which includes the OncAlert Oral Cancer RAPID Test and the OncAlert Oral Cancer LAB Test, both CE Marked and available in select markets outside the United States. Vigilant’s accurate, cost-effective tests can benefit every adult, with particular emphasis on high-risk populations (i.e., current and former tobacco users, those who consume excessive alcohol, and people with human papillomavirus).
About Oral Cancer
According to the World Health Organization, there are more than 529,000 new cases of oral (lip, oral cavity and pharynx) cancer each year worldwide, with mortality rates that reach up to 292,000 deaths each year. In the United States, more than 48,000 individuals will be diagnosed with oral cancer this year with more than 9,500 deaths resulting from this disease, killing roughly one person per hour, 24 hours per day. Historically the death rate associated with this cancer is particularly high due to late-stage diagnosis and intervention. Currently, the vast majority of patients are detected through a visual exam and/or are symptomatic, at which point they are likely late stage. As a result, oral cancer often goes undetected to the point of metastasizing.
For those who survive oral cancer diagnosed in the later stages, the treatment is painful, debilitating and often disfiguring. In addition, patients often struggle with eating and drinking, communicating and self-image. Early detection (stage I and II) of oral cancer yields survival rates of up to 90 percent.
About Vigilant Biosciences, Inc.
Vigilant Biosciences is a leading innovator and developer of solutions that aid clinicians in the early detection and intervention of cancer. The Vigilant Biosciences OncAlert® Oral Cancer product line and OncAlert Labs product line include point-of-care and lab-based products and services that are simple, accurate and cost-effective and that can empower healthcare practitioners to improve potential outcomes through earlier intervention. The OncAlert Oral Cancer LAB Test and the OncAlert Oral Cancer RAPID Test are CE Marked and available in select international markets outside the U.S. The OraMarkTM Test is a Laboratory Developed Test that is only available in the U.S. exclusively through OncAlert Labs, LLC, a CLIA-certified laboratory and a member of the Vigilant Biosciences family of companies. For more information, visit www.vigilantbiosciences.com and www.oncalertlabs.com.